Eylea, which is used to treat macular degeneration and other eye
disorders that cause age-related vision loss, raked in $953 million
in U.S. sales in the third quarter ended Sept. 30, beating consensus
estimates of $935 million, according to Barclays.
Excluding items, Regeneron earned $3.99 per share, above the
analysts' average estimate of $3.85, according to Thomson Reuters
I/B/E/S.
The U.S. biotechnology company said net income rose to $388.3
million, or $3.32 per share, in the third quarter from $264.8
million, or $2.27 per share, a year earlier.
Total revenue, which includes collaboration revenue from partners
Sanofi SA and Bayer AG, rose to $1.50 billion from $1.22 billion.
[to top of second column] |

(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by
Sriraj Kalluvila)

[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |